

In re Application of: H. KAWABATA, et al.  
 Serial No.: 09/358,755  
 Filed: July 22, 1999  
 For: NUCLEIC ACIDS ENCODING TRANSFERRIN RECEPTOR-LIKE PROTEINS



1646  
 Docket No. 81476-247716  
 Date: October 5, 2001  
 Examiner: J. Murphy  
 Art Unit: 1646

ASSISTANT COMMISSIONER FOR PATENTS  
 Washington, D.C. 20231

RECEIVED

OCT 17 2001

TECH CENTER 1600/2900

Sir:

Transmitted herewith is an amendment in the above-identified application.

- Small entity status of this application under 37 CFR 1.9 and 1.27 has been established by a verified statement previously submitted.
- A verified statement to establish small entity status under 37 CFR 1.9 and 1.27 is enclosed.
- Certified copy of Patent Application No. filed from which priority is claimed under 35 USC §119.
- No additional fee is required.

The fee has been calculated as shown below:

	(Col. 1) CLAIMS REMAINING AFTER AMENDMT		(Col. 2) HIGHEST NO. PREV. PAID FOR	(Col. 3) PRESENT EXTRA	SMALL ENTITY/ LARGE ENTITY RATE	ADDTL FEE DUE
TOTAL CLAIMS	34	Minus	29	5	X 9 X 18	90
IND. CLAIMS	4	Minus	4	0	X 42 X 84	
FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIMS					+ 280 + 140	
<b>TOTAL</b>						<b>\$90</b>

- \* If the entry in Col. 1 is less than the entry in Col. 2, write "0" in Col. 3.
- \*\* If the "Highest Number Previously Paid For" IN THIS SPACE is less than 20, write "20" in this space.
- \*\*\* If the "Highest Number Previously Paid For" IN THIS SPACE is less than 3, write "3" in this space. The "Highest Number Previously Paid For" (Total or Independent) is the highest number found from the equivalent box on Col. 1 of a prior amendment or the number of claims originally filed.

— Please charge my Deposit  
 Account No. 03-3975 the  
 amount of

\$0

A copy of this sheet is  
 enclosed.

X A check in the amount of

\$90

to cover the amendment filing fee  
 is enclosed. A copy of this  
 sheet is enclosed.

— Please charge my Deposit Account No. 03-3975 the amount of \$\_\_\_\_. A copy of this sheet is enclosed.


\_\_\_ A check in the amount of \$\_\_ to cover the extension fee is enclosed. **A copy of this sheet is enclosed.**

X The Commissioner is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. 03-3975. **A copy of this sheet is enclosed.**

X Any filing fees under 37 CFR 1.16 for the presentation of extra claims.

X Any patent application processing fees under 37 CFR 1.17.

Respectfully submitted,




Richard H. Zaitlen

Reg. No. 27,248

PILLSBURY WINTHROP LLP  
ATTORNEYS AT LAW  
725 South Figueroa Street, Suite 2800  
Los Angeles, CA 90017-5406  
Telephone: (213) 488-7100  
Facsimile: (213) 629-1033

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to:  
Assistant Commissioner for Patents  
Washington, D.C. 20231  
on October 5, 2001



10/5/01  
Richard H. Zaitlen, REG. NO. 27,248

PATENT  
81476-247716

#196  
10/18/01

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

H. KAWABATA et al.

Serial No: 09/358,755

Filed: July 22, 1999

For: NUCLEIC ACIDS ENCODING  
TRANSFERRIN RECEPTOR-LIKE PROTEINS



Art Unit: 1646

Examiner: J. F. Murphy

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to:  
Assistant Commissioner for Patents  
Washington D.C. 20231, on

October 5, 2001

Date of Deposit

Richard H. Zaitlen

Name

Signature

10/5/01

Date

AMENDMENT

RECEIVED

OCT 17 2001

Assistant Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

TECH CENTER 1600/2900

In response to the Office Action dated September 5, 2001, please enter and consider the following amendment and remarks:

IN THE CLAIMS:

Please cancel claims 10, 59, and 71 and amend claim 62 as follows:

C<sup>1</sup> 62. (Amended) The isolated host cell of claim 61, wherein the promoter is selected from the group consisting of T7, metallothionein I, and polyhedrin promoters.

Please add new claims 72-79 as follows:

C<sup>2</sup> 72. (New) RNA of claim 47 operatively linked to a promoter of RNA transcription.

10/15/2001 HNDOR1 00000025 09358755

01 FC:103

90.00 OP